SEC Comment Letter 0000000000-24-004748 to MoonLake Immunotherapeutics (MLTX) (CIK 0001821586) (MLTX)
MoonLake Immunotherapeutics (MLTX) (CIK 0001821586)
Date: April 29, 2024 · CIK: 0001821586 · Accession: 0000000000-24-004748
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39630
Letter
United States securities and exchange commission logo April 29, 2024 Matthias Bodenstedt Chief Financial Officer MoonLake Immunotherapeutics Dorfstrasse 29, 6300 Zug Switzerland Re:MoonLake Immunotherapeutics Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-39630 Dear Matthias Bodenstedt: We have limited our review of your filings to the financial statements and related disclosures and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-K for Fiscal Year Ended December 31, 2023 Exhibits 1.We note that your officers' Section 906 certifications furnished in Exhibits 32.1 and 32.2 pursuant to Rule 13-a14(b) of the Exchange Act refer to the year ended December 31, 2022 rather than for the year ended December 31, 2023. Please file a full amendment to your Form 10-K which includes corrected and currently dated Section 906 certifications. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameMatthias Bodenstedt Comapany NameMoonLake Immunotherapeutics April 29, 2024 Page 2 FirstName LastName Matthias Bodenstedt MoonLake Immunotherapeutics April 29, 2024 Page 2 Please contact Tara Harkins at 202-551-3639 or Lynn Dicker at 202-551-3616 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
April 29, 2024
Matthias Bodenstedt
Chief Financial Officer
MoonLake Immunotherapeutics
Dorfstrasse 29, 6300
Zug Switzerland
Re:MoonLake Immunotherapeutics
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-39630
Dear Matthias Bodenstedt:
We have limited our review of your filings to the financial statements and related
disclosures and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for Fiscal Year Ended December 31, 2023
Exhibits
1.We note that your officers' Section 906 certifications furnished in Exhibits 32.1 and 32.2
pursuant to Rule 13-a14(b) of the Exchange Act refer to the year ended December 31,
2022 rather than for the year ended December 31, 2023. Please file a full amendment to
your Form 10-K which includes corrected and currently dated Section 906 certifications.
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
FirstName LastNameMatthias Bodenstedt
Comapany NameMoonLake Immunotherapeutics
April 29, 2024 Page 2
FirstName LastName
Matthias Bodenstedt
MoonLake Immunotherapeutics
April 29, 2024
Page 2
Please contact Tara Harkins at 202-551-3639 or Lynn Dicker at 202-551-3616 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences